PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28560420-9 2017 TUNEL, Annexin V-fluorescein isothiocyanate/propidium iodide, and ratio of Bcl-2-associated X protein and B cell lymphoma 2 indicated that baicalein and U0126 induced HeLa cell apoptosis. U 0126 153-158 BCL2 apoptosis regulator Homo sapiens 75-80 30290166-9 2018 However, pre-incubation with the inhibitor of ERK (U0126), significantly increased the BAX/BCL2 ratio. U 0126 51-56 BCL2 apoptosis regulator Homo sapiens 91-95 27774945-12 2016 Treatment by baicalein alone or in combination with U0126 for 24 hours significantly decreased ERK1/2 and Bcl-2 mRNA expressions, and upregulated Bax mRNA expression. U 0126 52-57 BCL2 apoptosis regulator Homo sapiens 106-111 27888104-6 2017 Treatment with 10 or 20 muM U0126 followed by CGZ or TGZ induced the down-regulation of ERK1/2 activity and a decrease in Bcl-2 expression accompanied by the collapse of mitochondrial membrane potential, which in turn significantly enhanced CGZ- or TGZ-induced apoptotic cell death. U 0126 28-33 BCL2 apoptosis regulator Homo sapiens 122-127 27588132-10 2016 In addiiton, expression of LC3II/LC3I decreased and the expression of BAX/Bcl-2 increased in the matrine + U0126 group compared with the matrine alone group. U 0126 107-112 BCL2 apoptosis regulator Homo sapiens 74-79 25756510-7 2015 Mechanistically treatment of NBs with small molecule inhibitors of EGFR (erlotinib, cetuximab) and ERK (U0126) increases Noxa expression and dephosphorylates Bim to promote Bim binding to Bcl(-)2. U 0126 104-109 BCL2 apoptosis regulator Homo sapiens 188-195 26849940-6 2016 Furthermore, U0126, an ERK1/2 inhibitor, markedly down-regulated Bcl-2 level, up-regulated the levels of Bax, cleaved caspase-3/9, and enhanced Cytochrome c release inducted by dioscin. U 0126 13-18 BCL2 apoptosis regulator Homo sapiens 65-70 26035796-6 2015 The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist). U 0126 142-147 BCL2 apoptosis regulator Homo sapiens 18-35 26035796-6 2015 The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist). U 0126 142-147 BCL2 apoptosis regulator Homo sapiens 37-42 23220614-6 2013 Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3. U 0126 13-18 BCL2 apoptosis regulator Homo sapiens 88-93 24881958-6 2014 U0126 markedly increased UA-induced the Bax/Bcl-2 ratio, the increase of cytosol cytochrome c, and the levels of cleaved caspase-3, but SB203580 had little effects on the above characters, suggesting the ERK1/2 signaling pathway is required for apoptosis. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 44-49 23423712-12 2013 The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP. U 0126 17-22 BCL2 apoptosis regulator Homo sapiens 105-110 24319338-13 2013 However, unlike the SB216763-treated cells, the UO126-treated cells showed a marked absence of Bcl-2, as well as phosphorylated Bcl-2 relative to the controls. U 0126 48-53 BCL2 apoptosis regulator Homo sapiens 95-100 24319338-13 2013 However, unlike the SB216763-treated cells, the UO126-treated cells showed a marked absence of Bcl-2, as well as phosphorylated Bcl-2 relative to the controls. U 0126 48-53 BCL2 apoptosis regulator Homo sapiens 128-133 23403511-8 2013 Moreover, U0126 prevented the rapamycin-induced increase of Bcl-2 and VEGF-A levels. U 0126 10-15 BCL2 apoptosis regulator Homo sapiens 60-65 21159167-4 2010 RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells. U 0126 9-14 BCL2 apoptosis regulator Homo sapiens 99-103 21159167-4 2010 RESULTS: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1, ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARgamma) and drug metabolism (CYP3A4) genes newly identified in MM cells. U 0126 9-14 BCL2 apoptosis regulator Homo sapiens 133-137 14660675-7 2004 In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. U 0126 122-127 BCL2 apoptosis regulator Homo sapiens 46-51 15626723-9 2005 Moreover, U0126 and ERK siRNA inhibition completely suppressed asiatic acid-induced Bcl-2 phosphorylation and Bax up-regulation, and caspase-9 activation. U 0126 10-15 BCL2 apoptosis regulator Homo sapiens 84-89 15647742-7 2005 H89, KN62, and U0126 reduced CREB activation and Bcl-2 expression. U 0126 15-20 BCL2 apoptosis regulator Homo sapiens 49-54 15569266-5 2004 The effects of C2-ceramide and PACAP on Bax and Bcl-2 were blocked, respectively, by the JNK inhibitor L-JNKI1 and the MEK inhibitor U0126. U 0126 133-138 BCL2 apoptosis regulator Homo sapiens 48-53 15569266-8 2004 U0126 blocked PACAP-induced Bcl-2 expression, abrogated the inhibitory effect of PACAP on ceramide-induced caspase-9 activity, and promoted granule cell death. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 28-33 15184882-9 2004 DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. U 0126 132-137 BCL2 apoptosis regulator Homo sapiens 13-18 12056831-7 2002 At 4 and 6 h ischemia, U0126-treated astrocytes expressed a lower level of Bcl-2 than controls. U 0126 23-28 BCL2 apoptosis regulator Homo sapiens 75-80 14645670-5 2003 Coadministration of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or TNF-alpha substantially increased MEK inhibitors (e.g., PD184352 or U0126)/UCN-01-induced mitochondrial dysfunction, activation of procaspase-8 and Bid, and apoptosis in Bcl-2- and Bcl-xL-overexpressing cells but not in those in which the extrinsic pathway was interrupted. U 0126 161-166 BCL2 apoptosis regulator Homo sapiens 263-268 14506750-9 2003 Docetaxel plus U0126 had only 20% added effect on Bcl-2 phosphorylation compared to docetaxel alone. U 0126 15-20 BCL2 apoptosis regulator Homo sapiens 50-55 12689928-4 2003 UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 71-96 12689928-4 2003 UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis. U 0126 0-5 BCL2 apoptosis regulator Homo sapiens 98-103 12771938-10 2003 Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. U 0126 76-81 BCL2 apoptosis regulator Homo sapiens 19-24 11767000-6 2001 The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest. U 0126 18-23 BCL2 apoptosis regulator Homo sapiens 39-44 11777344-6 2002 Pretreatment of THP-1 cells with MEK inhibitors (U0126 and PD98059) prior to bryo1 induction blocked the expression of both XIAP and the c-fms product (M-CSF receptor), a hallmark of monocytic differentiation, but not Bcl-2. U 0126 49-54 BCL2 apoptosis regulator Homo sapiens 218-223 11767000-6 2001 The MEK inhibitor U0126 (U0) decreased Bcl-2 expression but not Mcl-1 expression, inhibited cells growth and induced G1/G0 arrest. U 0126 18-20 BCL2 apoptosis regulator Homo sapiens 39-44